Serina Therapeutics (SER) announced that the FDA has placed a clinical hold on the Investigational New Drug application for SER-252, Serina's lead development program for advanced Parkinsons disease. The FDA has requested additional information related to a commonly used excipient in the formulation.
Serina said it expects to receive the FDA's formal clinical-hold letter within 30 days and will provide an update once it has aligned with the FDA on next steps and timelines.
Shares of Serina Therapeutics are down 8% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.